Evidence map›Paper›PMID 38687401›Full record

ArticleMedical oncology (Northwood, London, England)2024

Drug-loaded polymer-coated silver nanoparticles for lung cancer theranostics.

Ranjita Misra, Subhenjit Hazra, Suraiya Saleem, Sushmitha Nehru

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer.Immunity, inflammation and disease · 2026
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ranjita MisraDepartment of Biotechnology, Centre for Research in Pure and Applied Sciences, School of Sciences, Jain University, Bangalore, 560027, Karnataka, India. ranjita.misra@jainuniversity.ac.in.ORCID http://orcid.org/0000-0002-3812-3669
Subhenjit HazraCentre for Nanoscience and Nanotechnology, Sathyabama Institute of Science and Technology, Chennai, 600119, India.
Suraiya SaleemDepartment of Biotechnology, Indian Institute of Technology, Madras, Chennai, 600036, Tamil Nadu, India.
Sushmitha NehruCentre for Nanoscience and Nanotechnology, Sathyabama Institute of Science and Technology, Chennai, 600119, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the leading cause of death in cancer across the globe. To minimize these deaths, the replacement of traditional chemotherapy with novel strategies is significant. We have developed a nanotheranostic approach using silver nanoparticles for imaging and treatment. Silver nanoparticles (AgNPs) are fabricated by chemical reduction method. The formulation of AgNPs was confirmed by different characterization techniques like stability test, UV-Visible spectroscopy, Confocal Raman Spectroscopy, and Energy-Dispersive X-ray analysis. Further, AgNPs are coated with poly lactic-co-glycolic acid (PLGA) and then loaded with paclitaxel (Pac). Then the drug-loaded PLGA-coated AgNPs were characterized for size and zeta potential measurement by zetasizer, surface morphology study by atomic force microscopy, Fourier transform infrared spectroscopy, and release kinetics study. The imaging and anticancer properties of these nanoformulations are investigated using lung cancer cell lines. The results proved that the particles are in the nanometer range with smooth surface morphology. Moreover, the drug-loaded NPs showed a sustained release of the drug for a longer period of time. Further the formulations showed imaging property with greater anticancer efficacy. Thus, the results suggest the effective use of these nanoformulation in both lung cancer imaging and treatment using a simple and efficient approach.

Indexed as

Lung NeoplasmsMetal NanoparticlesPaclitaxelPolylactic Acid-Polyglycolic Acid CopolymerSilverTheranostic NanomedicineA549 CellsCell Line, TumorHumansPaclitaxelPolylactic Acid-Polyglycolic Acid CopolymerSilverLung cancerNanotheranosticsPaclitaxelPLGASilver nanoparticles

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.